Form 4: Centessa Pharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals, sold 16,619 ordinary shares at an average price of $15.6883 per share under a pre-arranged trading plan.
Summary
- Gregory M. Weinhoff, the Chief Business Officer of Centessa Pharmaceuticals plc, reported the sale of 16,619 ordinary shares on September 25, 2024.
- The shares were sold at a weighted average price of $15.6883.
- The sales were executed under a Rule 10b5-1 trading plan adopted on May 22, 2024.
- Following the transaction, Weinhoff directly owns 206,750 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to an executive's stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment, but rather a routine transaction.
Industry Context
Executive share sales are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan allows insiders to sell shares without being accused of trading on non-public information.
Stakeholder Impact
- The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 05/22/2024 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| 09/25/2024 | Date of the transaction (share sale) |
| 09/27/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.